SPRY

ARS Pharmaceuticals, Inc. (SPRY) Business Model Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Revenue Quality

Gross margin remains strong at 77.1% TTM, indicating a high-quality product revenue mix.

Revenue per share is 0.997 TTM, but the company is still unprofitable with net income per share of -1.994 TTM.

Profitability

Operating margins remain deeply negative, with EBIT margin at -197.6% and operating profit margin at -204.5% TTM.

Return on equity is -153.6% TTM and return on invested capital is -85.0% TTM, showing the business is still far from profitable.

Balance Sheet

Liquidity is strong with a current ratio of 4.94x and quick ratio of 4.77x TTM.

Debt appears manageable relative to market value, with debt-to-market-cap at 16.1% and net debt to EBITDA at -0.38x TTM.

Cash Flow

Free cash flow remains negative, with free cash flow per share at -1.766 TTM and free cash flow yield at -29.3%.

Operating cash flow is also negative at -1.763 per share TTM, indicating the business is still consuming cash.

Efficiency

Asset turnover is modest at 0.34x TTM, suggesting limited revenue generation from the asset base.

Working capital remains positive at 195.6M, but the cash conversion cycle is long at 174.9 days TTM.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ARS Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →